Assessment of the safety and effectiveness of COVID-19 vaccines during pregnancy.
(1) Effectiveness (89.5%) of mRNA vaccination (2) Reduction in stillbirth (the risk significantly lower by 15% mRNA vaccination in pregnancy appears to be safe).
No evidence of a higher risk of adverse outcomes (miscarriage, earlier gestation at birth, placental abruption, pulmonary embolism, postpartum hemorrhage, maternal death, intensive care unit admission, lower birthweight).
Assessment of safety, immunogenicity, effectiveness, acceptance of COVID-19 vaccination among pregnant people in the United States.
11 examined COVID-19 vaccine safety, 10 investigated immunogenicity and effectiveness, 11 assessed vaccine acceptance among pregnant people COVID-19 vaccination, pregnant women with a robust immune response, and vaccinations conferred protective immunity to newborns through breast milk and placental transfer.
Injection-site pain and fatigue are the most common adverse events One case study showed immune thrombocytopenia COVID-19 vaccination did not increase the risk of adverse pregnancy or neonatal outcomes.
Studying the role of/provide an update regarding COVID-19 vaccines during pregnancy, breastfeeding.
Reduction of the risk of severe COVID-19 in pregnant women after COVID-19 vaccination Induction artificial active immunogenicity in the mother and natural passive immunogenicity in the child Breastmilk straddles both immediate antibody-mediated and long-lived cellular-mediated immune protection Neonatal benefits Vaccination associated with a larger and more stable immunoglobulin G response COVID-19 infection associated with a rapid and long-lasting immunoglobulin A response Strong recommendation of COVID-19 vaccines for pregnant and breastfeeding populations to protect mothers and newborns.
Main adverse effect (pain at the injection site, as in the general population) Adverse effects more frequent after the second dose, slightly more frequent after the Moderna vaccine.
Assessment of the current knowledge about maternal and neonatal outcomes following COVID-19 vaccination during pregnancy and breastfeeding Estimation of how many pregnant and lactating women were vaccinated and with maternal and neonatal outcomes.
Recommendation for vaccination against the SARS-CoV-2 virus for pregnant women Infants received specific SARS-CoV-2 antibodies after maternal vaccination Still limited evidence that fever during the first months of gestation increases the possibility of congenital anomalies, should be carefully counseled The same considerations apply to breastfeeding women, also considering the immune responses that mRNA vaccines can generate in their human milk.
No major side effects especially during the second and third trimesters of pregnancy and during breastfeeding.
157,521 singleton births (103,409 Sweden 54,112 Norway), 157,521 singleton pregnancies.
Estimation of the risk of adverse pregnancy outcomes after vaccination against SARS-CoV-2 during pregnancy identification of exposure and background characteristics mRNA vaccines: BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), one vaccine-AZD1222 (AstraZeneca).
The risk of preterm birth and stillbirth was evaluated The risk of being small for gestational age, low Apgar score, and neonatal care admission was evaluated using logistic regression The mean maternal age at the time of delivery was 31 years, and 28,506 (18%) were vaccinated (12.9% BNT162b2, 4.8% mRNA-1273, and 0.3% AZD1222) while pregnant First (0.7%), second (8.3%), and third trimesters (9.1%) of individuals delivering Vaccination not significantly associated with increased risk of preterm birth (6.2 vs. 4.9 per 10,000 pregnancy days; aHR, 0.98) Stillbirth (2.1 vs. 2.4 per 100,000 pregnancy days; aHR, 0.86) Small for gestational age (7.8% vs. 8.5%; difference, -0.6%; aOR, 0.97), low Apgar score (1.5% vs. 1.6%; difference, -0.05%; aOR, 0.97; 95% CI, 0.87 to 1.08) Neonatal care admission (8.5% vs. 8.5%; difference, 0.003%; aOR, 0.97) In Sweden/Norway, vaccination during pregnancy, compared with no SARS-CoV-2 vaccination during pregnancy, was not significantly associated with an increased risk of adverse pregnancy outcomes The majority of the mRNA vaccines during the second and third trimesters of pregnancy.
Evaluation of the safety and probable outcomes of COVID-19 vaccination in pregnant women.
COVID-19 vaccination in pregnant women not associated with significant health risks, increased adverse effects, or complications to the mother, developing foetus, or newborn compared to nonvaccinated pregnant women Vaccinated pregnant women showed a robust immune response against COVID-19 infection.
Evaluation of the outcomes of women who received the COVID-19 vaccine during pregnancy.
SARS-CoV-2 exposure during pregnancy related to adverse effects for both the mother and the infant SARS-CoV-2 vaccination lowered the risk of symptomatic disease The rate of neonates with 5 min Apgar score ≤ 7 Pregnant mothers with preterm birth significantly lower among vaccinated groups No evident differences observed among vaccinated pregnant mothers.
COVID-19 vaccination not associated with adverse pregnancy and neonatal outcomes.
Assessment of the maternal and neonatal safety of the COVID-19 vaccine during pregnancy.
No statistically significant difference of SAR-CoV-2 vaccination on the risk of outcomes: miscarriage, length of maternal hospitalisation, puerperal fever postpartum hemorrhage, instrumental or vacuum-assisted delivery incidence of at 5 min, birth weight.
42 studies of COVID-19 vaccination during pregnancy 96,384 (73.9%) BNT162b2, 30,889 (23.7%) mRNA-1273, 3172 (2.4%) other types 23,721 (18.3%) first trimester, 52,778 (40.5%) second trimester, 53,886 (41.2%) third trimester.
Evaluation of the safety of COVID-19 vaccination during evaluation of the association of COVID-19 vaccination during pregnancy with adverse maternal and neonatal outcomes.
Reduced risks of stillbirth or neonatal death COVID-19 vaccination during pregnancy not associated with congenital anomalies, preterm birth, NICU admission, or hospitalisation with an Apgar score at 5 min < low birth weight miscarriage, caesarean delivery, or postpartum hemorrhage.
COVID-19 vaccination during pregnancy not associated with any of the adverse neonatal or maternal outcomes.
Assessment of COVID-19 vaccination’s efficacy and safety during pregnancy; comparison of the incidence of major maternal and neonatal outcomes between SARS-CoV-2-vaccinated and SARS-CoV-2-unvaccinated pregnant women.
Reduction by 43% of the rate of SARS-CoV-2 infections among vaccinated pregnant women SARS-CoV-2 vaccination in pregnant women effective and safe.
SARS-CoV-2 vaccines not associated with major maternal and neonatal adverse events.
